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A growing number of new studies demonstrate that nuclear receptors are involved in the development of alcoholic liver disease
(ALD). Ethanol metabolism and RXR/PPAR functions are tightly interconnected in the liver. Several ethanol metabolizing enzymes
are potently regulated by RXR and PPARα after alcohol consumption. The increased ethanol metabolism, in turn, leads to
alteration of the redox balance of the cells and impairment of RXR/PPAR functions by direct and indirect effects of acetaldehyde,
resulting in deranged lipid metabolism, oxidative stress, and release of proinflammatory cytokines. The use of animal models
played a crucial role in understanding the molecular mechanisms of ALD. In this paper we summarize the reciprocal interactions
between ethanol metabolism and RXR/PPAR functions. In conclusion, RXR and PPAR play a central role in the onset and
perpetuation of the mechanisms underling all steps of the clinical progression in ALD.
Copyright © 2009 Tommaso Mello et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1. Introduction
Alcoholic liver disease, which includes a spectrum of liver
injury that covers from the relatively benign alcoholic fatty
liver to the potentially fatal alcoholic hepatitis and cirrhosis,
has a known etiology but a complex pathogenesis resulting
from a combination of genetic, environmental, nutritional,
metabolic, and more recently, immunologic factors as well as
cytokines [1–4].
Fatty liver is the most frequent hepatic abnormality
found in alcoholics as a toxic manifestation of ethanol
ingestion. Fatty livermay occur alone or be part of the picture
of alcoholic hepatitis or cirrhosis and the development of
these late alterations is not clearly understood.
In the liver, ethanol is metabolized to acetaldehyde by
two systems: the cytosolic, largely uninducible, aldehyde
dehydrogenase (ADH) and the ethanol inducible microso-
mal cytochrome P4502E1 [5, 6]. Mitochondrial acetaldehyde
dehydrogenase (ALDH) is then responsible for the further
oxidation of acetaldehyde to acetate (a nontoxic metabolite)
using NAD+ as a substrate.
Ethanol complete degradation produces a large amount
of reducing agents in the form of NADH (from ADH and
ADLH catalyzed reactions) and NADPH (from cytochrome
P4502E1) that overwhelm the hepatocyte’s ability to main-
tain redox homeostasis. Moreover the altered redox state
impairs gluconeogenesis, diverts acetyl-CoA toward ketoge-
nesis and fatty acid synthesis, and diminishes lipid oxidation
disrupting fatty acids β-oxidation [7]. Recent works indicate
that reactive oxygen species play a major role in alcohol
induced liver injury: CYP2E1 ethanol degradation in the
presence of iron generates reactive oxygen species (ROS) thus
increasing oxidative stress and leading to membrane-lipids
oxidation [8], furthermore oxidative stress depletes the cell
reservoir of reduced glutathione (GSH), vitamin E, and S-
adenosyl methionine (SAM) [9–12]. These altered mecha-
nisms, along with oxidative stress, are however insufficient
to account for all the effects of ethanol consumption and
recent works highlight the importance of nuclear receptors
and transcription factors in the pathogenesis of liver disease.
Inflammation is important in the progress of alcoholic
liver disease with Kupffer cell being the master regulator
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(see for recent reviews [1, 2]). In alcoholics and in ethanol-
treated animals plasma LPS levels increase; moreover steato-
sis and ethanol consumption bring to intrahepatic inflam-
mation due to Kupffer cells deregulated release of inflamma-
tory cytokine (especially TNF-α). Several possibilities have
been proposed to explain the increase of plasma LPS induced
by alcohol. Clinical and experimental studies demonstrated a
bacterial outgrowth after ethanol administration [13]; how-
ever LPS diffuses from intestine at very low levels. The main
mechanism involved appears to be an increased intestinal
permeability. Numerous studies demonstrated that ethanol
disrupts the functional and structural integrity of intestinal
epithelial cells resulting in cellular hyperpermeability and
gut leakiness [14–16]. Oxidative stress and toxic metabo-
lites accumulation in intestine may explain the increased
permeability. Acetaldehyde, produced by ethanol oxidation
in intestine, disrupts intestinal epithelial tight junctions and
increases paracellular permeability to endotoxins in Caco-2
cell monolayer [17]. Furthermore, ethanol induces, in vitro
and in vivo, the overproduction of nitric oxide, mediated
by the inducible nitric oxide synthase [18, 19] that causes
intestinal barrier dysfunction trough oxidation and nitration
of cytoskeletal proteins [20].
Liver depleted of Kupffer cells shows a decrease in
tissue damage induced by ethanol feeding [21]. Kupffer cells
produce a large amount of inflammatory citokines, especially
TNF-α. Kupffer cells from fed-ethanol animals are more
susceptible to LPS due to increased expression of Toll-like
receptor 4 (TLR-4) [22] that binds LPS and regulates TNF-α
secretion [23]. Accumulating evidences suggest that ethanol
sensitizes Kupffer cells to LPS through the production of
reactive oxygen species (ROS) by NAPDH oxydase and
CYP2E1 [24].
Other important factors for the development of alcoholic
liver disease whose role became more clear in the last years
are some adipokines, such as adiponectin [2] and leptin [25,
26], that are involved in the control of the alcohol induced
inflammatory and fibrogenic response.
Chronic exposure to ethanol inhibits the activity and/or
downregulates the expression of several lipid metabolism
regulating enzymes, foremost AMP-activated kinase
(AMPK) [27], peroxisome proliferator activated receptors
(PPARs) [28], retinoid X receptors (RXRs) [29], and sirtuin1
(SIRT1) and 5 (SIRT5) [30, 31], whereas up-regulates the
sterol regulatory element-binding protein 1 (SREBP-1)
[32]. The mechanisms by which ethanol consumption
causes accumulation of hepatic triacylglycerols are complex.
AMP-activated protein kinase (AMPK) has a pivotal role in
the regulation of lipid metabolism; its activation increases
fatty acid oxidation and reduces their synthesis. AMPK
activity in liver of ethanol-fed rats is decreased and less
sensitive to changes in the AMP/ATP ratio facilitating
triacylglycerol accumulation [27]. Activation of SREBP-1
by ethanol feeding is associated with increased expression
of hepatic lipogenic genes as well as the accumulation of
triglycerides in the livers [32].
Alcohol significantly reduces SIRT1 and SIRT5 expres-
sion [30, 31, 33–35]: cytoplasmic SIRT1 and mitochondrial
SIRT5 are (NAD+)-dependent deacetylase that regulate the
activity of histonic and nonhistonic proteins [36, 37]. They
are important regulators of energy metabolism control-
ling the gluconeogenic genes and hepatic glucose output
through PGC-1α deacetylation (and hence the gluconeoge-
nesis/glycolitic pathway) [30, 31, 38–40]; in addition, SIRT1
modulates the effects of PGC-1α repression of glycolytic
genes in response to fasting and pyruvate [39]. Knockdown
of SIRT1 in liver causes mild hypoglycemia, increases sys-
temic glucose and insulin sensitivity, and decreases glucose
production. SIRT1 knockdown also decreases serum choles-
terol and increases hepatic free fatty acids (FFAs) and choles-
terol content [40]. Ethanol administration induces PGC-1α
and p53 hyperacetylation that could be partially ascribed
to SIRT1 and SIRT5 reduced expression; posttranslational
modifications of these proteins inactivate PGC-1α and p53
physiological functions and are associated with mitochon-
drial dysfunction [30, 31]. Sirtuins may also regulate lipid
metabolism: SIRT-1 mediates SBREP-1 activation by ethanol
regulating its acetylation. In fact, inhibition of hepatic SIRT1
activity is associated with an increase in the acetylated active
nuclear form of SREBP-1c in the livers of ethanol-fed mice
[33]. Moreover in ethanol-fed mice, resveratrol, a potent
SIRT agonist, prevents alcoholic liver steatosis suppressing
SREBP-1 and activating PGC-1a [35].
PPARα forms heterodimers with RXR to regulate and
bind to PPAR response elements (PPREs) of genes involved
in the regulation of fatty acid oxidation and transport.
Ethanol reduces PPARα activity and RXR protein levels;
these reductions are associated to the inhibition of fatty acid
oxidation [28, 29].
A growing number of new studies demonstrate that
PPAR and RXR nuclear receptors are involved in many
aspects of the development of alcoholic liver disease, ranging
from ethanol oxidation to regulation of ethanol-induced
inflammatory responses.
In this paper we will summarize the progress in the
understanding of ethanol metabolism regulation by PPAR
and RXR nuclear receptors in alcoholic liver disease.
2. Role of PPAR in Alcoholic Liver Disease
In the past decade the role of PPAR receptors in the
development of ALD has been intensively investigated, both
in cell culture systems and in ethanol-fed rodents. The
emerging picture is a complex network of alcohol-induced
deregulation of all PPAR isoforms, involving different cell
types and mechanisms.
2.1. PPARα in Alcoholic Liver Disease. PPARα is a master
regulator of lipid metabolism in the liver, controlling the
expression of genes involved in the transport, oxidation,
and export of free fatty acids. Increased levels of FFA
in the hepatocyte activate PPARα by direct binding to
the receptor and thus inducing the expression of genes
involved in the mitochondrial and peroxisomal FFA β-
oxidation pathways. In addition to increasing fatty acids
disposal through oxidative degradation, PPARα also inhibits
the lipogenic pathway by induction of the malonyl Co-A
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decarboxylase, thus promoting the degradation of malonyl
Co-A, a precursor of fatty acid biosynthesis [9].
Since fatty liver represents a very common finding in
ALD, the effect of ethanol metabolism on PPARα regulated
processes has been intensively investigated in the past ten
years.
In cultured hepatoma cells ethanol affects PPARα tran-
scriptional activity by inhibiting the ability of the receptor to
bind its PPRE consensus sequences. This effect is dependent
on the ability of the cell tometabolize ethanol to acetaldehyde
as it was abolished by the ADH inhibitor 4-methylpirazole
and enhanced by the ALDH inhibitor cyanamide. More-
over, administration of acetaldehyde alone to cultured cells
inhibited PPARα binding to DNA, strongly suggesting that
acetaldehyde is responsible for the effects of ethanol [28].
In vivo experiments on ethanol-fed rodents reported
animal-specific differences on the effects of ethanol on
hepatic PPARα protein levels. In Sv/129 mice and in rats,
ethanol administration decreased PPARα protein levels [41–
43]. Activation of PPARα by clofibrate in ethanol-fed rats
ameliorates fatty liver and decreased necroinflammatory
injury [43]. On the other hand, in ethanol-fed C57BL/6J
mice PPARα protein levels did not change substantially; how-
ever PPARα/RXR binding to DNA was significantly impaired
and some PPARα target genes (as medium chain acyl
CoA dehydrogenase) were downregulated [29]. Although
the observed reduction in RXR protein level in ethanol-fed
mice could certainly account for the reduced PPARα/RXR
DNA binding, induction of PPARα alone by its agonist
WY14,643 restored PPARα/RXR binding activity by inducing
PPARα but not RXR protein levels, thus revealing that also
a reduced activation of PPARα mediates the ethanol effects
in vivo. The restored PPARα/RXR binding by WY14,643
administration to ethanol-fed mice was accompanied by an
increase of the mRNA of PPARαtarget genes, some of which
were actually either not downregulated by ethanol feeding,
such as acyl-CoA oxidase, carnitine palmitoyl transferase-
1 (CPT-1), very-long chain acyl CoA dehydrogenase and
synthetase, or even induced by ethanol, such as L-fatty acid
binding protein (L-FABP) [29]. The induction of PPARα
target genes by WY14,643 was accomplished even with
concomitant administration of ethanol, indicating that this
ligand prevents the effect of ethanol on PPARα, possibly
by increasing the fraction of DNA-bound PPAR/RXR and
thus minimizing the post-translational modifications of the
PPARαDNAbinding domain by acetaldehyde [2, 29]. PPARα
activation by WY14,643 restored the fatty acid β-oxidation,
normalized serum fatty acid and trygliceride levels, and
prevented fatty liver in ethanol-fed mice.
Taken together these data suggests that if on one hand
ethanol may not completely impair the basal expression of
many PPARα target genes, on the other hand it severely
reduces the ability of the receptor to induce the lipid
oxidative metabolism and detoxification systems, as it is
required in response to increased fatty acids intake and
alcohol consumption. This line of thought seems to be
supported by the experiments conducted in PPARα null
mice. In fact in these animals several PPARα regulated
genes like the peroxisomal acyl-CoA oxidase, the bifunctional
enzyme enoyl-CoA:hydratase-3-3-hydroacyl-CoA dehydro-
genase, CYP4A and L-FABP were constitutively expressed at
levels comparable to wild-type animals [44, 45].
However, the induction of both peroxisomal and mito-
chondrial β-oxidation pathways by clofibrate or WY14,643
was completely abolished in PPARα−/− mice [41, 45,
46]. Moreover, PPARα null mice were found to have a
marked reduction in the expression of ALDH, which led to
increased acetaldehyde levels, increased lipid peroxidation
and oxidative stress. PPARα null mice were thus significantly
more sensitive to ethanol induced liver damage than wild-
type animals [41].
A role for PPARα in hepatic inflammation has also
been well established. PPARα null mice have a prolonged
inflammatory response through the leukotriene B4 (LTB4)
and its receptor compared to wild-type mice [47]. In
fact LTB4 is a ligand of PPARα, that acts as an anti-
inflammatory receptor stimulating LTB4 degradation in the
β-oxidative pathways [48]. Moreover, activation of PPARα
antagonizes NF-kB signalling, thus preventing the expression
of several proinflammatory genes, such as C-reactive pro-
tein, fibrinogen –α and –β, acute-phase response proteins,
serum amyloid A [49]. Therefore inhibition of PPARα
transcriptional activity by acetaldehyde not only deranges the
physiologic lipid metabolism leading to increased ROS and
lipid peroxide production, but also stimulates the release of
pro-inflammatory cytokines from hepatocytes.
2.2. PPARγ in Alcoholic Liver Disease. While ethanol
metabolism in the liver occurs largely in hepatocytes, its
oxidative product, acetaldehyde, easily diffuses to neighbours
cells altering their physiologic processes. In the progression
of ALD the activation of Hepatic Stellate Cells (HSCs) is a
key step that leads to fibrosis and cirrhosis. Works by our
group and others [50–52] demonstrated the importance of
PPARγ in the activation of HSC. Active PPARγ is required
for the maintenance of the resting “fat storing” phenotype
by HSC, and its expression and transcriptional activity
decrease during cell activation in culture. Moreover PDGF, a
potent inducer of HSC proliferation and migration, induces
inactivation of PPARγ by phosphorylation [50, 51]. The
decrease in PPARγ transcriptional activity results in an
increased synthesis of fibrillary collagens, while activation of
the receptor by thiazolidinediones (TZDs) ligands was able
to reduce the collagen synthesis in HSC both in vitro and
in vivo [53]. The mechanism of PPARγ inhibition in human
HSC by ethanol metabolism is rather complex. We found
that acetaldehyde inhibits PPARγ by a MAPK mediated
phosphorylation on Ser84. The phosphorylation of PPARγ
was demonstrated to be dependent on a pathway involving c-
Abl, PKCδ, and ERK1/2, and to be initiated by acetaldehyde
through a H2O2 dependent mechanism [54]. The signalling
axis acetaldehyde-H2O2-PKC-ERK1/2 in mediating the pro-
fibrogenic response of HSC is well established [55–57], and
H2O2 produced in Kupffer cells induces collagen deposition
by HSC [58]. Therefore, inhibition of PPARγ by phospho-
rylation can potentially occur as a consequence of several
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diverse processes taking place during the ethanol-induced
liver injury.
Inflammation plays a central role in the onset and
progression of ALD. PPARγ ligands inhibited the pro-
inflammatory behaviour of HSC downregulating the mono-
cyte chemotactic protein-1 (MCP-1) [51]. Pioglitazone pre-
vents liver injury by ethanol and LPS in rats [59, 60]. In this
model, activation of PPARγ by pioglitazone was shown to
reduce the production of TNFα by activated Kupffer cells.
Kupffer cells are able to metabolize ethanol [61, 62] and
chronic ethanol consumption induces CYP2E1 expression
in Kupffer cells [63]. Although in acute alcohol induced-
liver injury acetaldehyde has been shown to inhibit TNF-α
release by Kupffer cells through inhibition of the NF-kB
pathway [64, 65], in chronic alcohol abuse the role of Kupffer
cell activation and TNF-α release in promoting liver injury is
well established. It is therefore tempting to speculate that in
ALD acetaldehyde, produced in Kupffer cells or hepatocytes,
could lead to suppression of PPARγ transcriptional activity
and promote the release of TNF-α. Indeed, enhanced release
of TNF-α in response to acetaldehyde or LPS by Kupffer
cells isolated from ethanol-fed rats has been reported
[66, 67]. Moreover, in ALD increased TNF-α release by
Kupffer cells does occur by LPS stimulation due to increased
intestinal permeability (described elsewhere in this review).
Circulating LPS binds to LPS binding protein (LBP) [68]
which promotes its interaction with the Kupffer cells’
CD14 cell-surface receptor. This complex interacts mainly
with the toll-like receptor 4 (TLR4), which in turn transduces
the down-stream signal through activation of the PCK,
MAPK, and NF-kB signalling pathways [69]. Furthermore,
ethanol induces the expression of CD14/TLR-4 receptors in
kupffer cells, thus “priming” the liver macrophage popula-
tion to respond to LPS stimulation, and this sensitization
was found to depend upon NADPH oxidase mediated-
oxidative stress and activation of the NF-kB pathway [22,
70]. TNF-α is also known to downregulate PPARγ function
by several mechanisms (see Ye 2008 for a recent review
[71]), and LPS treatment was shown to downregulate PPARγ
expression in Kupffer cells both in vitro and in an animal
model of sepsis through a TNFα -dependent mechanism
[72].
Finally, a link between CYP2E1 and TNF-α production
has been described in vitro in a macrophage cell line with
stable expression of CYP2E1 [24]. In this model, increased
expression of CYP2E1 was accompanied by increased levels
of CD14/TLR-4, NADPH oxidase, and H2O2. The higher
production of hydrogen peroxide resulted in activation of
the MAPKs ERK1/2 and p38, which stimulated TNF-α
production via activation of NF-kB and stabilization of TNF-
α mRNA, respectively [24].
Although these interlinked events still need to be
substantiate in an animal model of ALD, the emerging
picture describes a likely redundant mechanism by which
ethanol induction of CYP2E1 and NADPH oxidase systems
enhances oxidative stress and sensitizes Kupffer cells to
endotoxins, thus promoting inflammation by inhibition
of PPARγ function and activation of NF-kB pathways.
This line of thought seems to be supported by recent
evidences demonstrating that TLR-4 mediates the LPS-
induced downregulation of PPARγ by a NF-kB dependent
mechanism in macrophages [73]. Loss of PPARγ activity
was sufficient to induce a pro-inflammatory state, indicating
that PPARγ suppress inflammation under basal conditions
by repressing NF-kB activity, while upon activation of TLR4,
NF-kB drives down PPARγ expression and thereby obviates
any potential anti-inflammatory effects of PPARγ in LPS-
stimulated macrophages [73].
2.3. PPARβ/δ and Ethanol. PPARβ/δ is probably the less
characterized isoform of the PPAR family. It is expressed in
a large array of tissues, including central nervous system,
liver, adipose tissue, muscles, and the gastrointestinal tract.
In skeletal and cardiac muscle PPARβ/δ is expressed at
much higher levels than PPARα and PPARγ [74, 75].
Recent studies suggest that, in the adult, PPARβ/δ plays
important roles inmaintaining the glucose-lipid homeostasis
by stimulating fatty acid oxidation and uncoupling of the
respiratory chain in the muscle, by inhibiting glucose and
VLDL secretion from the liver, by stimulating the cholesterol
efflux increasing circulating HDL levels; moreover PPARβ/δ
is also implicated in the regulation of the inflammatory
activity of macrophages (for recent reviews on the metabolic
action of PPARβ/δ see [76, 77]).
Very little is known about the effect of ethanol on
PPARβ/δ. In rat hepatoma cells, acetaldehyde inhibited
PPARβ/δ DNA binding activity but at a much higher
concentration than that required for PPARα inhibition [28].
PPARβ/δ is also expressed in hepatic stellate cells, and its
expression increases with cell activation in vitro and in
vivo [78, 79]. However, the role of this PPAR isoform in
stellate cells is of difficult interpretation, since if on one
hand it promotes hepatic stellate cells proliferation [79], on
the other it induces genes involved in the esterification of
Vitamin A such as CRBP-1 and LRAT, possibly reflecting
a compensatory mechanism aimed to counterbalance the
loss of retinol storage during activation [78]. Very recently,
the mRNA levels of PPARβ/δ have been shown to increase
in livers of ethanol fed-rats [80]; however in this model
activation of PPARβ/δ by the specific agonist L165,041
resulted in an attenuation of the ethanol-induced hepatic
injury and in an improvement of liver regeneration [80].
Ethanol is known to disrupt insulin signalling [81–83]
and to impair liver regeneration [84]. According to recent
data demonstrating a role for PPARβ/δ in the regulation
of glucose metabolism and insulin sensitivity [85], the
protective effects of PPARβ/δ agonist on ethanol-induced
liver injury were shown to be dependent on the amelioration
of the insulin binding to insulin and IGF-1 receptors and
activation of the down-stream signalling pathways [80].
An important role for PPARβ/δ in the regulation of the
inflammatory profile of tissuemacrophages has been recently
discovered [86, 87]. Odegaard and coworkers showed that
PPARβ/δ is required for alternative activation of Kupf-
fer cells, and alternatively activated macrophages suppress
inflammation and promote tissue repair [87, 88]. Moreover,
alternatively activated Kupffer cells promote the β-oxidative
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pathways and suppress lipogenesis in hepatocytes via a
paracrine cross-talk [87]. The mouse model used by Odeg-
gard and coworkers was developed to study obesity-induced
insulin resistance and type-2 diabetes; however since several
parallelisms exist between alcoholic and nonalcoholic liver
injury [23], it would be of great interest to test the hypothesis
that macrophage specific inhibition of PPARβ/δ would play
an important role in alcohol-induced steatohepatitis.
PPARβ/δ null mice show defective myelination of
the corpus callosum, reduced adipose tissue and altered
inflammatory response in the epidermis [89]. In B12
oligodendrocyte-like cells ethanol was shown to selectively
reduce PPARβ/δ expression by increased mRNA degradation
without affecting PPARα and PPARγ [90]. These obser-
vations could possibly undercover a mechanism underling
the ethanol-induced myelination defects and neurological
impairment in the foetus [91]. In a recent study by Venkata
et al. PPARα and β/δ were shown to be differentially affected
by acetaldehyde and ethanol, respectively. The authors show
that in MCF-7 breast cancer cell line acetaldehyde inhibits
PPARα but not PPARβ/δ, while the latter is inhibited directly
by ethanol [92]. A growing body of evidence suggests an
association between ethanol consumption and increased
cancer risk in different tissues, including breast [93, 94].
More studies are needed to elucidate the effects of ethanol
metabolism on PPARβ/δ and the underling mechanisms,
but it is intriguing to speculate that some effects of ethanol
on peripheral tissues could be mediated by this poorly
understood PPAR isoform.
3. RXRs, Ethanol Metabolism, and
Alcoholic Liver Disease
RXR is a nuclear receptor expressed in almost every cellular
type and tissue. Three isoforms of RXR have been found
in human, named RXRα, β, and γ, being the α-isoform the
most abundant in the liver [95]. Unique among the other
nuclear receptors, RXRα play a major modulatory role across
multiple cellular pathways forming mandatory heterodimers
with other nuclear receptors.
RXR β and γ apparently play minor roles in the liver:
it has been demonstrated in mice that RXRαnull/RXRγ
null and RXRβ null/RXRγ null mutant phenotypes were
indistinguishable from those of RXRα null and RXRβ null
mutants, and that the presence of a single allele of RXRα is
sufficient to perform most of RXR functions [96].
In the last years there has been an increasing interest
in the role of RXR, especially RXRα in alcoholic liver
disease. Accumulating evidence suggests that RXR may play
a major role in many aspects of ethanol metabolism being
its expression downregulated by ethanol [42, 97]. In fact,
mice fed with ethanol show reduced ability of PPAR/RXR
heterodimers to bind DNA and reduced RXR expression
[29]. These effects are acetaldehyde dependent because
blocking ADH reduces, while blocking ADLH increases, the
observed phenotype [28]. Moreover, the human aldehyde
dehydrogenase-2 promoter contains a retinoid response
element (designated FP330-3′), which may contribute to the
regulation of the gene. Heterodimers of retinoic acid receptor
(RAR)α, β, and γ with RXRα bound the FP330-3′ site,
stimulating the expression of reporter constructs containing
the FP330-3′ sites in a 9-cis retinoic acid-dependent fashion
in cultured cells.
More insights on RXR specific role in alcoholic liver
disease come from experiments with animal models mainly
from the group of Professor Wan JY that demonstrated an
altered ethanol methabolism in RXRα null mice.
Hepatocyte RXRα-deficient mice possess a phenotype
partially overlapping both PPARα and PPARγ knockout-
mice phenotypes. Like the PPARα-null mice, hepatocyte
RXRα-deficient mice are obese, have a larger fat mass, and
higher serum cholesterol and leptin levels compared with
wild-type mice; similar to PPARγ +/− mice, hepatocyte-
RXRα-deficient mice also have reduced food intake and
increased serum leptin levels [98]. On the contrary, hep-
atocyte RXRα deficiency results in an improved glucose
tolerance without altering insulin level or insulin sensitivity
[98].
RXRα deletion increases liver enzymatic activity of
ADH1 isoform without affecting ADH2 and ADH3 [12].
It has been suggested that RXRα may regulate ADH1
translation because mRNA levels were the same between null
and wild-type mice, while there is increased abundance of
ADH1 mRNA in the polysome fraction, indicating higher
translation in null mice. This latter effect may bemediated by
leptin whose levels are increased in RXR null mice [98] and
has been reported capable of regulating ADH activity [99].
RXR may regulate acetaldehyde oxidation to acetate and
its clearance. ALDH mRNAs (especially ALDH1 mRNA) are
reduced in null mice indicating a possible direct regulation
that would parallel with the above mentioned finding
that human ALDH promoter responds to RXR. Increased
ADH1 activity accounts for the rapid oxidation of ethanol
to acetaldehyde; reduced ALDH activity observed in RXR
deficient mice impairs the further oxidation to acetate
sensitizing the mice to the ethanol-induced damage.
RXR is able to regulate the expression of many xeno-
chemical metabolizing enzymes of the cytochrome P450
family acting as a dimerization agent for PPAR, LXR,
PXR [100–103], but its ability to regulate the cytochrome
P450 CYP2E1, involved in ethanol oxidation to acetalde-
hyde, needs further investigation. The promoter region of
cytochrome P4504A contains an imperfect direct repeat
sequence recognized by PPARα/RXR heterodimers and
P4504A is induced by peroxisome proliferators [104]
whereas CYP2B is induced by androstane receptor/RXR
heterodimers [105]. It has been demonstrated that ethanol-
fed animals show a reduced RXR expression whereas CYP2E1
mRNA increases [42, 97]. In an RXR null background, male
mice but not female have a reduced expression of CYP4A,
3A, CYP2A and CYP2B mRNA [10, 106] but not of CYP2E1
[106] compared to male wild-type mice. Furthermore, when
RXR null mice were challenged with ethanol, induction of
CYPs expression was lower in mutant mice compared to
wild-type mice [10]. In RXR KO mice CYP2E1 activity is
reduced [12] and the enzyme is not induced by ethanol
[107]. The apparent discrepancy between wild-type and RXR
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KOmice in the activation of cytochrome CYP2E1may be due
to residual RXR expression in ethanol-fed animals compared
to RXR KO mice where RXRα has been knocked out. It also
may suggest that RXR may play an important role in P450
regulation at the transcription and translational levels.
The altered expression of cytochrome enzymes in RXR
KO mice suggests that these mice could be less sensitive to
ethanol damage with respect to wild-type mice; however,
ethanol treated KO mice still show induced liver damage.
Toxic acetaldehyde accumulation due to altered ADL/ADLH
activities (as described above) may account for that damage
but other mechanisms are also involved.
It is well known that ethanol alters phase II metabolism
of xenobiotics agents [108]. Depletion of GSH reservoirs
reduces the liver ability to withstand oxidative stress from
altered redox equilibrium and to prevent lipids peroxidation
as a result of ethanol ingestion. Dai et al. [10] and Gyamfi
and Wan [109] demonstrated that GSH levels are reduced
in wild-type mice after ethanol administration; this effect is
exacerbated in RXR null mice [10, 109]. Compared to wild-
type mice, hepatocyte RXRα-deficient mice have significant
lower levels of SAM (a precursor for GSH synthesis) and
GSH, which is further reduced after alcohol treatment [10,
11]. The Glutathione S-transferase (GSTs) is a multigene
family of enzymes that bind GSH to xenobiotics agents
facilitating theirs dissolution in the aqueous cellular and
extracellular media, and, from there, out of the body.
GSTs are encoded by at least 9 gene family: eight of them
encode for cytosolic enzymes (namely, alpha, mu, theta, pi,
zeta, sigma, kappa and chi—also called omega) whereas a
ninth family, composed at least by six genes encode for
microsomal enzymes [110]. GST enzymes of alpha, mu, and
pi families account for the majority of cytosolic GST activity.
In RXR null mice GST activity and transcription is
reduced compared to wild-type mice [11, 12]. In hepato-
cytes, RXRα deficiency changes the gene expression profiles
of the GSTs: it has been reported that basal expression of
13 out of 15 GST genes was altered in hepatocyte-specific
RXRα-deficient mice [11], being either down or upregulated.
The enzymatic activity of both mitochondrial and cytosolic
GSTs is reduced in null mice [12]. Acute ethanol exposure of
primary mouse hepatocytes reduces GSH levels and cytosolic
GST enzymes activity along with the release of GST into
the culture medium. Specific substrates for the mu and pi
class demonstrate that ethanol significantly decreases the mu
and pi class GST activity by 53% and 13%, respectively.
These biochemical changes elicited by ethanol were also
accompanied by increased lipid peroxidation and a decreased
SAMe to SAH ratio, early biochemical features of ethanol
toxicity. Moreover, hepatocytes isolated from RXR KO mice
show a decrease of mu and pi class GST activity compared to
wild-type mice.
In H4IIE hepatocytes GSTA2 gene is induced by PPARγ
activator and 9-cis-retinoic acid. The TZD PPARγ agonists,
troglitazone, rosiglitazone, and pioglitazone, in combination
with retinoic acid, increase GSTA2 induction, confirming
that the activation of PPARγ/RXR heterodimer contributes
to GSTA2 expression [111]. Unique among the GSTs,
the alpha class isoenzymes have selenium independent
antiperoxidase activity [112]. It has been demonstrated that
alpha class GST [113–115] plays an important role in the
protection mechanisms against oxidative stress induced by
lipid peroxidation.
This latter finding suggests that in alcoholic liver disease
and ethanol metabolism, RXR regulation of GSTs expression
may be important not only for conjugation of toxic metabo-
lites to GSH but also for the protection against the deleterious
effects of lipid peroxidation.
Deranged lipid metabolism and steatosis is one of
the hallmark of heavy ethanol consumption. The role of
nuclear receptors (especially PPARα) in the control of lipid
metabolism is well known and has been already extensively
reviewed [1, 2, 116, 117]; however, some specific effects,
observed in ethanol fed-animals and previously ascribed to
the PPARα pathway, could indeed be RXR specific [98, 118].
When fastened or treated with WY14,643, RXR null mice
show a phenotype in several aspects different from PPAR
null mice. Apolipoprotein A-I and C-III mRNA levels, serum
cholesterol and triglyceride levels are markedly induced in
untreated RXR null but not in PPARα-null mice. Moreover,
fasting-induced PPARα activation and WY14,643 effects are
reduced in RXR KO mice. Acyl-CoA oxidase, medium chain
acyl-CoA dehydrogenase, and malic enzyme induction by
WY14,643 are reduced in null mice without altering their
mRNA levels [118].
In RXR null mice L-FABP levels are dramatically reduced
compared to wild-type animals [107]. L-FABP is a PPARα
target gene and is necessary for the transport of fatty acids.
Ethanol feeding increases hepatic FFA levels both in wild-
type and null mice; however in RXR null mice L-FABP is
not induced by ethanol and this effect is associated with
accumulation of FFA and ethanol induced liver damage
[107]. A recent paper from Razny et al. further demonstrated
the RXR specific role on lipid metabolism and angiogenesis.
Microarray studies on RXRα deficient mice fed with a high-
fat diet for 7 weeks demonstrated a down-regulation of genes
related to angiogenesis, whereas genes involved in adipogene-
sis, apoptosis, and inflammation were upregulated. Based on
these results Razny et al. suggested that impaired fatty acid
metabolism in liver leads to impaired angiogenesis due to
lipotoxicity and promotion of adipogenesis [119].
Liver damage resulting from chronic ethanol consump-
tion is also caused by inflammatory processes. As previously
reported, in alcoholics increased LPS levels and altered
metabolism induce inflammation, worsening alcoholic liver
disease, and Kupffer cells are more sensitive to LPS due
to increased expression of Toll-like receptor 4 [23]. In the
negative acute hepatic phase response, LPS induces a down-
regulation of lipid metabolism associated with increased
serum triglyceride levels and reduced lipid β-oxidation.
These effects appear to be mediated by a reduction of
nuclear receptors expression mediated by TNF-α and IL-
1 but not IL-6 [120]. RXRα expression is lower in LPS
negative acute hepatic phase response [101] and HepG2 IL-
1 β-cells showed a marked decline in RAR/RXR binding to
the Ntcp gene that regulates bile flow [121]. The alteration
of RXR pathways is associated with changes in its sub-
cellular localization characterized by increased cytoplasmic
PPAR Research 7
and reduced nuclear levels [122]. The nuclear residence of
RXRα is maintained inhibiting c-jun N-terminal kinase or
CRM-1-mediated nuclear export, while IL-1 increases the
proteasome mediated RXR degradation [123].
Interestingly, hepatocytes from ethanol-fed RXR null
mice show an increased NF-kB activation and a strong and
higher induction of inflammatory cytokines TNF-α, IL-1
and IL-6, compared to wild-type mice [107]. Apoptosis in
RXR null mice increases after ethanol ingestion due to a
lower expression of antiapoptotic proteins Bcl2 and Bcl-XL,
even in the presence of higher levels of IL-6. RXR seems
to influence IL-6/STAT3 mediated signalling circumventing
STAT3 phosphorylation [107]. This suggests that RXR is an
important regulator of inflammatory processes in response
to ethanol; it may also be speculated that some of the effects
in response to LPS (as describer above) may be ascribed to
RXR reduced expression.
Finally, ethanol and retinoid metabolisms are widely
interconnected [124]. Liver from alcoholics shows a marked
depletion of Vitamin A that correlates with the activation of
stellate cells, their loss of lipid droplets and differentiation
in myofibroblast-like cells. The role of nuclear receptors
in stellate cells activation is widely studied and it is
reported elsewhere in this paper. Key enzymes in ethanol
metabolismmay act also on retinol pathway [125]. Enhanced
activities of ADH, ALDH, and CYP2E1 in alcoholics may
account for the observed reduction of Vitamin A in liver
cells. Even if retinol it is not their supposed primary substrate
it is well known that ADHs and ALDHs may catalyze the
conversion of Vitamin A to retinoic acid accelerating retinol
metabolism; furthermore alcohol induction of cytochrome
CYP2E1 determines a higher rate of Vitamin A catabolism
in polar metabolites in the liver. Ethanol may also increase
retinol mobilization from liver increasing hydrolization of
retinyl esters [126–128]. Alcohol-induced effects on retinol-
regulated genes are further increased by RXR downreg-
ulation observed in alcohol-fed animals. This establishes
a complex regulatory mechanism between RXR, retinol
metabolism, and ethanol that is deregulated during heavy
ethanol consumption.
4. Summary and Conclusions
Ethanol metabolism and RXR/PPAR functions are tightly
interconnected in the liver. Several ethanol metabolizing
enzymes are potently regulated by RXR and PPARα after
alcohol consumption. The increased ethanol metabolism,
in turn, lead to alteration of the redox balance of the
cell and impairment of RXR/PPAR functions by direct
and indirect effects of acetaldehyde, resulting in deranged
lipid metabolism, oxidative stress, and release of pro-
inflammatory cytokines. In this paper we summarized the
reciprocal interaction between ethanol metabolism and
RXR/PPAR functions.
The use of alcohol-fed rodents played a crucial role in
understanding the molecular mechanisms of ALD. However,
important differences exist in the regulation of the oxidative
metabolism between rodents and humans. In fact, while in
rodents the need for increased oxidative metabolism induces
peroxisome proliferation, humans exclusively respond by
increased mitochondrial β-oxidation. Moreover, the levels
of PPARα receptor are markedly lower in humans than in
rodents, and this may be even more striking during alcohol
abuse. PPAR and RXR KO mouse models highlighted the
reciprocal regulation of PPAR, RXR and ethanol in alcoholic
liver disease. In conclusion, RXR, and PPAR play a central
role in the onset and perpetuation of the mechanisms
underlying all steps of the clinical progression in alcoholic
liver disease.
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